在阿尔茨海默病中改变小脑激活模式:激活概率估计元分析
Jessica A Bernard1, Ivan A Herrejon2, Emily An2
1Department of Psychological and Brain Sciences Texas A&M University, United States; Texas A&M Institute for Neuroscience Texas A&M University, United States.
NeuroImage. Clinical
|March 23, 2025
概括
小脑越来越多地与阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 有关. 这次元分析发现,在AD中没有显著的小脑激活重叠,但在MCI中确实如此,这表明对功能和行为的负面影响.
科学领域:
- 神经科学是一个神经科学.
- 认知神经学 认知神经学
- 神经成像是一种神经成像.
背景情况:
- 小脑在非运动功能和神经退行性疾病 (如阿尔茨海默病 (AD) 和轻度认知障碍 (MCI)) 中的作用正在引起人们的注意.
- 虽然它不是AD病因学的核心,但小脑病理和缩越来越被认可.
- 小脑作为皮质活动的支架的功能可能延伸到AD和MCI,尽管AD中的功能成像是新生的.
研究的目的:
- 使用元分析研究在阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 中功能小脑激活的重叠.
- 探索AD/MCI患者和认知正常的老年人 (OA) 之间小脑激活的群体差异.
主要方法:
- 使用了激活概率估计 (ALE) 的元分析.
- 分析了29项研究的数据,其中包括236名阿尔茨海默病患者,159名MCI患者和382名OA患者.
- 探索性分析包括基于AD搜索参数的MCI.
主要成果:
- 在AD的研究中没有发现小脑激活的显著重叠.
- 在MCI中观察到小脑激活的显著重叠.
- 组分析表明,与OA相比,AD/MCI中小脑激活增加和减少的模式与OA相比.
- 重叠的主要区域是Crus I和Lobule VI.
结论:
- 大脑小脑功能似乎在阿尔茨海默病 (AD) 中受到负面影响.
- 这些小脑变化可能会影响AD相关的行为和症状.
- 这些发现凸显了小脑在超出运动控制的神经退行性疾病中的参与.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.8K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.8K
相关概念视频
Alzheimer's Disease: Overview
399
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
399
Alzheimer's Disease: Treatment
137
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
137
